Swedish medical technology company Elekta is showcasing its latest advances in precision cancer treatment at the 9th China International Import Expo in Shanghai from Thursday to Tuesday, including a comprehensive multi-modality adaptive radiotherapy ecosystem, as it expands its research and manufacturing capabilities in China, said a senior executive.
The Stockholm-based company is also releasing the China MRgRT (magnetic resonance-guided radiotherapy) White Paper 2026, featuring clinical findings on magnetic resonance-guided radiotherapy, and is marking the production of its 1,000th high-energy medical linear accelerator at its Beijing factory.
Participating in the CIIE for the ninth consecutive year and already signed up for the 10th edition, Elekta is advancing its technological innovations as China seeks to strengthen medical innovation and improve access to quality healthcare services under its 15th Five-Year Plan (2026-30) and broader Healthy China Initiative.
Gong Anming, president for China at Elekta, said the company is shifting from introducing global technologies to developing innovations locally and bringing Chinese clinical experience to international markets.
Elekta's Unity system, which made its Asian debut at the inaugural CIIE in 2018, has since been introduced at 17 medical institutions across China, benefiting more than 15,000 patients, Gong said.
"The next step is to move further from local manufacturing to local innovation," he said, stressing that China is one of Elekta's most important strategic markets and a key part of the company’s global research and development, manufacturing and supply chain network.
The Swedish company’s Beijing facility serves as a major production and innovation base, while Shanghai is home to its largest software development center worldwide. The company achieved localized production across its entire product portfolio in China in 2025, with equipment manufactured locally now exported to more than 130 countries and regions.
As artificial intelligence plays a growing role in radiotherapy, Gong said Elekta's AutoART technology combines AI-powered computing, automated visual checks and real-time monitoring to reduce adaptive radiotherapy workflows to between 10 and 15 minutes, making the process two to three times more efficient than conventional online adaptive radiotherapy.
Beyond technological advances, Gong identified the wider adoption of precision radiotherapy as a major growth opportunity in China's healthcare market, where hospitals increasingly need standardized and practical solutions.
Chen Jianwei, a researcher at the University of International Business and Economics' Academy of China Open Economy Studies in Beijing, said foreign medical technology companies are advancing China's healthcare development through technological innovation, local research, manufacturing investment and collaboration with hospitals.
"Their growing investment is also helping China develop a more sophisticated medical technology ecosystem and improve access to high-quality healthcare services," Chen said.
